Venture Life Group PLC Trading update (7615K)
July 12 2017 - 2:00AM
UK Regulatory
TIDMVLG
RNS Number : 7615K
Venture Life Group PLC
12 July 2017
12 July 2017
Venture Life Group plc
("Venture Life" or "the Group")
Trading update for the 6 months ended 30 June 2017
28% growth in revenues
Venture Life Group plc (AIM: VLG), the international consumer
self-care group focused on developing, manufacturing and
commercialising products for the ageing population, today provides
a trading update for the six months ended 30 June 2017.
-- Unaudited revenues for the six months ended 30 June 2017 were
GBP7.8m, 28% higher than the same period last year (H1 2016:
GBP6.1m)
-- On a like for like basis (including a full 6 months of
Periproducts revenues for H1 2016) this is growth of 18% over H1
2016
-- Periproducts (UltraDEX UK) recorded its highest month of
revenue in June for at least the last 5 years
-- Record month in Biokosmes as it recorded its largest ever revenue for a single month in June
-- 4 new deals signed internationally, including one on UltraDEX
June has seen the second UltraDEX promotional campaign in 2017
in the UK, which included TV advertising and promotions through
independent coffee shops amongst other activities. July will also
see the launch of the newly refreshed range of packaging in our
major pharmacy partner, along with the launch of the UltraDEX
sensitive range and new one litre packs sizes. There was also
confirmation in the first half of the year that store penetration
will increase (taking effect in July 2017), with 1,503 new listings
of UltraDEX in stores across the UK with our major pharmacy
partner.
Commenting, Chief Executive Officer, Jerry Randall, said: "The
first half of 2017 has shown continued growth and momentum in the
business. The UltraDEX acquisition is now fully integrated and
delivering the synergies and profitability expected. It is also
attracting good interest internationally. This has validated our
decision to make the acquisition and also proves the model we have
for utilising the good operational leverage that we have which is
available for future acquisitions. I am delighted with the
continued organic growth of the business in challenging markets and
in particular, that we have delivered a record level of sales
during June in both Biokosmes, and UltraDEX."
For further information please contact:
+44 (0) 1344
Venture Life Group PLC 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated Adviser +44 (0) 20
and Joint Broker) 3861 6625
Matthew Johnson / Edward Hutton / Margarita
Mitropoulou (Corporate Finance)
Bob Pountney / John Howes (Corporate
Broking)
+44 (0) 20
Turner Pope Investments (TPI) Ltd (Joint Broker) 3621 4120
James Pope / Ben Turner
Walbrook PR venturelife@walbrookpr.com
or + 44 (0) 20 7933 8780
Paul McManus / Anna Dunphy +44 (0) 7980 541 893 /
+44 (0) 7876 741 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the ageing population. The Group's product portfolio includes
some key products such as the UltraDEX oral care products range,
food supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
haemorrhoids and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTOKDDPQBKDPOD
(END) Dow Jones Newswires
July 12, 2017 02:00 ET (06:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024